Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada
PLoS ONE October 24, 2024 Kyurim Kim, Abban Yusuf, Abhimanyu Sud et al. 1 citation
Psychedelic clinics in Ontario, Canada, advertise psychedelics such as ketamine, MDMA, and psilocybin for 47 medical conditions, most commonly depression. An analysis of 10 clinic websites found that only 2 mentioned potential risks. The clinics cited 29 studies, the majority of which were case-series and case-control studies (level 4 evidence, the second lowest quality). Overall, the evidence quality supporting the clinics' claims was low to moderate. The study underscores the need for transparent, high-quality evidence to ensure safe and effective use of psychedelics in mental health treatment.